In addition, mutations in PTPN11 modulate serum HDL-C and are associated with hemostatic pathways such as platelet activation, aggregation, and sensitization [40, 41], as well as major genes associated with hypertension, ischemic heart disease, leukemia, and breast cancer [42]. Here, PTPN11 is linked to leukemia.